Sildenafil (Revatio®) is recommended, within its current licensed indication, as an option for use within NHS Wales for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity. AWMSG recommends that its use be restricted to a physician experienced in the treatment of PAH in association with a National Commissioning Group designated expert centre. AWMSG is of the opinion that sildenafil (Revatio®) is not suitable for shared care between primary and secondary care within NHS Wales.